Kolltan Pharmaceuticals, Inc. - Product Pipeline Review - 2016

  • ID: 3641089
  • Company Profile
  • 38 pages
  • Global Markets Direct
1 of 4
Kolltan Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Summary

‘Kolltan Pharmaceuticals, Inc. - Product Pipeline Review - 2016’, provides an overview of the Kolltan Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Kolltan Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Kolltan Pharmaceuticals, Inc.
- The report provides overview of Kolltan Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Kolltan Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Kolltan Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Kolltan Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Kolltan Pharmaceuticals, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Kolltan Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Kolltan Pharmaceuticals, Inc. Snapshot

Kolltan Pharmaceuticals, Inc. Overview

Key Information

Key Facts

Kolltan Pharmaceuticals, Inc. - Research and Development Overview

Key Therapeutic Areas

Kolltan Pharmaceuticals, Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Kolltan Pharmaceuticals, Inc. - Pipeline Products Glance

Kolltan Pharmaceuticals, Inc. - Clinical Stage Pipeline Products

Phase I Products/Combination Treatment Modalities

Kolltan Pharmaceuticals, Inc. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Kolltan Pharmaceuticals, Inc. - Drug Profiles

KTN-0158

Product Description

Mechanism of Action

R&D Progress

KTN-3379

Product Description

Mechanism of Action

R&D Progress

KIT-SG3227

Product Description

Mechanism of Action

R&D Progress

KTN-0182A

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody Conjugate to Antagonize ALK Receptor for Oncology

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody Conjugate to Inhibit Axl for Cancer, Inflammation and Infection

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody Conjugate to Target ErbB-3 for Oncology

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Inhibit c-MET for Cancer

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Inhibit DDR for Cancer and Osteoporosis

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Inhibit FGFR4 for Cancer

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Inhibit MERTK for Cancer, Inflammation and Infection

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Inhibit RON for Cancer

Product Description

Mechanism of Action

R&D Progress

Kolltan Pharmaceuticals, Inc. - Pipeline Analysis

Kolltan Pharmaceuticals, Inc. - Pipeline Products by Target

Kolltan Pharmaceuticals, Inc. - Pipeline Products by Route of Administration

Kolltan Pharmaceuticals, Inc. - Pipeline Products by Molecule Type

Kolltan Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action

Kolltan Pharmaceuticals, Inc. - Recent Pipeline Updates

Kolltan Pharmaceuticals, Inc. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Kolltan Pharmaceuticals, Inc., Key Information

Kolltan Pharmaceuticals, Inc., Key Facts

Kolltan Pharmaceuticals, Inc. - Pipeline by Indication, 2016

Kolltan Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016

Kolltan Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016

Kolltan Pharmaceuticals, Inc. - Phase I, 2016

Kolltan Pharmaceuticals, Inc. - Preclinical, 2016

Kolltan Pharmaceuticals, Inc. - Discovery, 2016

Kolltan Pharmaceuticals, Inc. - Pipeline by Target, 2016

Kolltan Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016

Kolltan Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016

Kolltan Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016

Kolltan Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016

Kolltan Pharmaceuticals, Inc., Subsidiaries

List of Figures

Kolltan Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016

Kolltan Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016

Kolltan Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016

Kolltan Pharmaceuticals, Inc. - Pipeline by Target, 2016

Kolltan Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016

Kolltan Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll